PTC Therapeutics (PTCT) Competitors $43.84 +0.76 (+1.76%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends PTCT vs. ITCI, SMMT, MRNA, RDY, CTLT, SRPT, QGEN, PCVX, ASND, and ROIVShould you be buying PTC Therapeutics stock or one of its competitors? The main competitors of PTC Therapeutics include Intra-Cellular Therapies (ITCI), Summit Therapeutics (SMMT), Moderna (MRNA), Dr. Reddy's Laboratories (RDY), Catalent (CTLT), Sarepta Therapeutics (SRPT), Qiagen (QGEN), Vaxcyte (PCVX), Ascendis Pharma A/S (ASND), and Roivant Sciences (ROIV). These companies are all part of the "pharmaceutical products" industry. PTC Therapeutics vs. Intra-Cellular Therapies Summit Therapeutics Moderna Dr. Reddy's Laboratories Catalent Sarepta Therapeutics Qiagen Vaxcyte Ascendis Pharma A/S Roivant Sciences PTC Therapeutics (NASDAQ:PTCT) and Intra-Cellular Therapies (NASDAQ:ITCI) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, valuation, risk, media sentiment and community ranking. Does the media prefer PTCT or ITCI? In the previous week, Intra-Cellular Therapies had 25 more articles in the media than PTC Therapeutics. MarketBeat recorded 43 mentions for Intra-Cellular Therapies and 18 mentions for PTC Therapeutics. PTC Therapeutics' average media sentiment score of 0.31 beat Intra-Cellular Therapies' score of 0.30 indicating that PTC Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PTC Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 7 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Intra-Cellular Therapies 6 Very Positive mention(s) 6 Positive mention(s) 23 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral Is PTCT or ITCI more profitable? Intra-Cellular Therapies has a net margin of -14.07% compared to PTC Therapeutics' net margin of -50.32%. PTC Therapeutics' return on equity of 0.00% beat Intra-Cellular Therapies' return on equity.Company Net Margins Return on Equity Return on Assets PTC Therapeutics-50.32% N/A -16.44% Intra-Cellular Therapies -14.07%-9.93%-8.38% Which has more risk and volatility, PTCT or ITCI? PTC Therapeutics has a beta of 0.62, meaning that its stock price is 38% less volatile than the S&P 500. Comparatively, Intra-Cellular Therapies has a beta of 0.7, meaning that its stock price is 30% less volatile than the S&P 500. Does the MarketBeat Community believe in PTCT or ITCI? PTC Therapeutics received 40 more outperform votes than Intra-Cellular Therapies when rated by MarketBeat users. However, 67.53% of users gave Intra-Cellular Therapies an outperform vote while only 61.89% of users gave PTC Therapeutics an outperform vote. CompanyUnderperformOutperformPTC TherapeuticsOutperform Votes56261.89% Underperform Votes34638.11% Intra-Cellular TherapiesOutperform Votes52267.53% Underperform Votes25132.47% Which has better earnings & valuation, PTCT or ITCI? Intra-Cellular Therapies has lower revenue, but higher earnings than PTC Therapeutics. Intra-Cellular Therapies is trading at a lower price-to-earnings ratio than PTC Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPTC Therapeutics$937.82M3.61-$626.60M-$5.94-7.38Intra-Cellular Therapies$464.37M28.81-$139.67M-$0.87-145.06 Do insiders and institutionals hold more shares of PTCT or ITCI? 92.3% of Intra-Cellular Therapies shares are held by institutional investors. 5.5% of PTC Therapeutics shares are held by company insiders. Comparatively, 2.6% of Intra-Cellular Therapies shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Do analysts prefer PTCT or ITCI? PTC Therapeutics currently has a consensus target price of $55.00, suggesting a potential upside of 25.46%. Intra-Cellular Therapies has a consensus target price of $100.31, suggesting a potential downside of 20.52%. Given PTC Therapeutics' higher possible upside, research analysts plainly believe PTC Therapeutics is more favorable than Intra-Cellular Therapies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PTC Therapeutics 3 Sell rating(s) 3 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 2.47Intra-Cellular Therapies 0 Sell rating(s) 6 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 2.67 SummaryIntra-Cellular Therapies beats PTC Therapeutics on 10 of the 17 factors compared between the two stocks. Get PTC Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PTCT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PTCT vs. The Competition Export to ExcelMetricPTC TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.38B$6.58B$5.36B$9.13BDividend YieldN/A2.95%5.13%4.03%P/E Ratio-7.389.8389.4717.33Price / Sales3.61308.061,264.56137.35Price / Cash18.1461.4443.7535.97Price / Book-4.046.055.324.80Net Income-$626.60M$154.62M$122.60M$224.91M7 Day Performance-0.23%-1.68%0.69%1.77%1 Month Performance-6.76%-2.35%1.55%2.22%1 Year Performance56.01%1.02%27.25%20.67% PTC Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PTCTPTC Therapeutics4.4915 of 5 stars$43.84+1.8%$55.00+25.5%+56.0%$3.39B$937.82M0.001,410Analyst ForecastAnalyst RevisionNews CoverageHigh Trading VolumeITCIIntra-Cellular Therapies3.8 of 5 stars$127.26+34.1%$97.23-23.6%+91.4%$13.49B$612.78M-146.27560Analyst ForecastHigh Trading VolumeSMMTSummit Therapeutics2.8416 of 5 stars$18.02+1.0%$33.57+86.3%+468.1%$13.29B$700,000.00-64.35105MRNAModerna4.7373 of 5 stars$34.19-19.1%$78.83+130.6%-66.1%$13.16B$5.06B-5.875,600Analyst ForecastOptions VolumeAnalyst RevisionNews CoverageHigh Trading VolumeRDYDr. Reddy's Laboratories2.0121 of 5 stars$15.28-0.9%$17.00+11.3%+10.6%$12.75B$3.35B24.4127,048News CoverageCTLTCatalent1.2524 of 5 stars$63.48flat$63.40-0.1%N/A$11.52B$4.42B-28.0916,900News CoverageSRPTSarepta Therapeutics4.9442 of 5 stars$117.14-6.1%$178.71+52.6%+0.8%$11.19B$1.64B93.711,314Analyst ForecastAnalyst RevisionNews CoverageQGENQiagen4.0945 of 5 stars$45.97+2.9%$51.50+12.0%-0.2%$10.49B$1.97B117.875,967Short Interest ↓News CoveragePCVXVaxcyte1.9897 of 5 stars$80.53-0.7%$145.71+80.9%+35.7%$10.04BN/A-17.51160Insider TradeAnalyst RevisionNews CoverageASNDAscendis Pharma A/S3.6193 of 5 stars$131.74+2.0%$192.07+45.8%-3.2%$8.00B$327.43M-16.30640Short Interest ↓ROIVRoivant Sciences3.689 of 5 stars$10.68+0.5%$17.93+67.9%+3.6%$7.77B$129.13M1.89860Insider TradeOptions VolumePositive News Related Companies and Tools Related Companies ITCI Alternatives SMMT Alternatives MRNA Alternatives RDY Alternatives CTLT Alternatives SRPT Alternatives QGEN Alternatives PCVX Alternatives ASND Alternatives ROIV Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:PTCT) was last updated on 1/18/2025 by MarketBeat.com Staff From Our PartnersLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds f...StocksToTrade | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredTrump Insider: Day One will Shock EveryoneA rare opportunity for everyday Americans like you to turn a small stake into real wealth in the stock market....InvestorPlace | SponsoredStunning Trump Exec Order LeakedMost people have no clue this unassuming facility exists. Yet the minute Donald Trump takes office... ...Banyan Hill Publishing | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredInvesting Tools You’ll Need for 2025Investing Tools You’ll Need for 2025 Charles Payne Shares His #1 Strategy for 2025 Unstoppable Prosperity | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PTC Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share PTC Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
